Healthcare / BiotechnologyNasdaqCM
$2.08
-0.04 (-1.89%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-11.1M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$361M
P/E
17.3x
↓EV/EBITDA
N/A
•ROE
-13.0%
↓Gross Margin
N/A
•Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.65x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-16.8M · FCF $-10.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | — | — | — | $250000.00 | — | — | — | — | — | $260000.00 | $16246.00 | $10417.00 | $18833.00 | $110000.00 | $407708.00 | $390625.00 | $733438.00 | — |
| Net Income | $-16.8M | $-16.8M | $-14.4M | $-12.3M | $-14.3M | $-26.6M | $-10.3M | $-8.4M | $-4.9M | $-15.7M | $-21.1M | $-20.9M | $-22.6M | $-19.8M | $-10.1M | $-12.5M | $-18.4M | $-10.4M |
| EBITDA | $-16.8M | $-16.8M | $-14.4M | $-12.3M | $-14.2M | $-41.9M | $-9.3M | $-8.5M | $-8.1M | $-13.0M | $-20.3M | $-18.8M | $-17.1M | $-12.3M | $-9.9M | $-12.8M | $-15.1M | $-10.4M |
| EPS | -0.30 | -0.30 | -10.19 | -27.01 | -247.95 | -2546.10 | -2790.00 | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | -5138.0% | — | — | — | — | — | -5118.1% | -127027.2% | -183896.8% | -92581.4% | -11385.4% | -2491.1% | -3325.6% | -2070.4% | — |
| Net Margin | — | — | — | -4920.0% | — | — | — | — | — | -6025.4% | -129721.8% | -200671.0% | -120154.7% | -18029.0% | -2482.5% | -3204.7% | -2507.0% | — |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.00 | 0.00 | 0.02 | 0.03 | 0.03 | 0.00 | -0.01 | — | — | — | — | 0.68 | 0.45 | 0.59 | 0.00 | — | — | — |
| Current Ratio | 23.71 | 23.71 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-10.8M | $-10.8M | $-12.2M | $-11.1M | $-13.4M | $-14.8M | $-4.8M | — | $-7.7M | $-13.4M | $-15.7M | — | — | — | $-8.5M | $-8.3M | $-10.1M | $-5.2M |
| Returns | ||||||||||||||||||
| ROE | -13.0% | -13.0% | -192.7% | -108.7% | -114.3% | -361.4% | 62.2% | 100.2% | -81.4% | -184.0% | -186.0% | -420.8% | -127.7% | -235.6% | -145.2% | -754.2% | -234.1% | 206.6% |
| Valuation | ||||||||||||||||||
| P/E | 17.33 | 17.33 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 0.89 | 0.89 | 0.36 | 0.32 | 0.20 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | — | — | — | — | — | — | — | — | — | 1500.4% | 56.0% | -44.7% | -82.9% | -73.0% | 4.4% | -46.7% | — | — |
| EPS Growth | 97.1% | 97.1% | 62.3% | 89.1% | — | 8.7% | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+181.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-10.19 → -0.30
Residual
+181.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.